Navigation Links
Handa Pharmaceuticals Announces Submission of Its First-to-File ANDA for Takeda's DEXILANT®
Date:3/2/2011

FREMONT, Calif., March 2, 2011 /PRNewswire/ -- Handa Pharmaceuticals, LLC ("Handa"), a specialty pharmaceutical company based in Fremont, California, today confirmed that its Abbreviated New Drug Application ("ANDA") for Dexlansoprazole Delayed Release Capsules, 60 mg, a generic version of Takeda's DEXILANT®, has been accepted for review by the U.S. Food and Drug Administration ("FDA"). Based upon available information, Handa believes that it is the first applicant to file an ANDA for DEXILANT® containing a Paragraph IV certification, under the provisions of the Hatch-Waxman Act. Should its ANDA for Dexlansoprazole Delayed Release Capsules, 60 mg, be approved by the FDA, Handa believes that the product may be entitled to 180 days of generic market exclusivity.

According to IMS Health, annual sales of DEXILANT® Delayed Release Capsules, 60 mg, in the U.S. were about $300 million for the twelve months ended December 31, 2010.

About Handa Pharmaceuticals, LLC Handa Pharmaceuticals, LLC is a specialty pharmaceutical company that was established in the San Francisco Bay area in November 2005. Handa's executive leadership has a proven track record of developing controlled-release prescription pharmaceutical products that are difficult to formulate. In December 2010, Handa announced that the U.S. Food and Drug Administration ("FDA") had granted tentative approval of the Company's Abbreviated New Drug Application ("ANDA") for Quetiapine Fumarate Extended-Release Tablets, 50 mg, 150 mg, 200 mg, 300 mg, and 400 mg, a generic version of AstraZeneca's SEROQUEL XR®. Handa is the first applicant to file an ANDA for SEROQUEL XR® 50 mg, 150 mg, 200 mg, and 300 mg containing a Paragraph IV certification, under the provisions of the Hatch-Waxman Act. For more information, please visit http://www.handapharma.com.

Forward-Looking Statements

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Handa's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Handa disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Handa's current expectations depending upon a number of factors affecting Handa's business. These factors include, among others, patents and other intellectual property rights held by competitors and other third parties and the uncertainty of the outcome of litigation related to such patents and intellectual property rights; the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approvals or actions; the impact of competitive products and pricing; market acceptance of and demand for Handa's products; difficulties or delays in manufacturing; and other risks and uncertainties.

DEXILANT® is a registered trademark of Takeda Pharmaceuticals North America, Inc.

SEROQUEL® and SEROQUEL XR® are registered trademarks of the AstraZeneca group of companies.Company Contact: Stephen CaryExecutive Vice President and COO Handa Pharmaceuticals, LLC(510) 354-2888stephen.cary@handapharma.comhttp://www.handapharma.comThis press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>

SOURCE Handa Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
2. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
3. N30 Pharmaceuticals to Present S-Nitrosoglutathione Reductase Inhibitor Preclinical Safety Data at 2011 Society of Toxicology 50th Anniversary Meeting
4. Lexicon Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
5. Anadys Pharmaceuticals to Present at the Cowen & Company Healthcare Conference
6. Access Pharmaceuticals to Host Update Conference Call for Investors
7. Optimer Pharmaceuticals to Present at March 2011 Investor Conferences
8. Jazz Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Results Conference Call on March 7
9. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
10. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
11. OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... 2017 Avillion LLP, a co-developer and financier ... Weinberg , MD MBA as Chief Medical Officer. Dr Weinberg will ... . ... Weinberg has spent more than 17 years as a pharmaceutical and ... micro-cap biotech. Over the course of his career, he has interfaced ...
(Date:1/19/2017)... , Jan. 19, 2017 Report Details ... Devices Market? Which areas are going to grow at ... revenues to 2026, assessing data, trends, opportunities and prospects. ... graphs. Discover the most lucrative areas in the industry ... you assess forecasted sales across the all the major ...
(Date:1/19/2017)... -- Conference Call and Webcast to Follow Vanda Pharmaceuticals ... release results for the fourth quarter of 2016 on Wednesday, February ... ... 4:30 PM ET on Wednesday, February 15, 2017, during which management ... and other corporate activities. To participate in the conference call, please ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... ... Chocolate Biscuit”: a biographical account following a man who went on to support his country ... Ivey, born in Lynn Haven, Florida and at the age of 5, his family moved ... he joined the Navy and got married right out of boot camp. , He ...
(Date:1/20/2017)... ... , ... “Christmas in Suffolk”: a story of love, secrets, and mystery. ... Lafayette, Indiana where she works in a daycare and looks for inspiration in the ... Christian Faith Publishing, Sara Seymour’s new book is an adventure of love and secrets. ...
(Date:1/20/2017)... ... ... Land of More and More”: a brilliant story for children and adults alike ... achievable answer. “The Land of More and More” is the creation of published author, ... where he works with the children’s ministry department. , Michael says that he ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... Aerolib Learning Management System: an On-demand E-learning system for Clinical and Regulatory ... Administration that is based on Aerolib`s successful education methodology of Disease Specific ...
(Date:1/19/2017)... ... January 19, 2017 , ... With the cold weather here, many people will have to ... efficient when clearing large amounts of snow, but they can be dangerous when used incorrectly. ... Product Safety Commission for the proper use of snow blowers:, , ...
Breaking Medicine News(10 mins):